Merck & Co. reported a 1 percent rise in quarterly revenue, driven by higher sales of its cancer drug, Keytruda. » Read More
For Cephalon, a company in Frazer, Pa., whose business tactics have attracted federal attention, the approval for jet lag is part of a plan to extend patent protection for its core franchise in stay-awake drugs.
GlaxoSmithKline is getting into the movie business, pursuing an unusual and most likely controversial strategy to increase interest in a weight-loss drug. The New York Times reports.
No one in their right mind, especially in this economy, likes to see someone lose their job. (Well, unless you really can't stand the person.) But, on the other hand, when you hear the top exec of the world's biggest drug company talk candidly about how much fat there was (is?) at Pfizer, can you really blame him for swinging the ax?
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
Time magazine's Man of the Year Ben Bernanke gave a speech this past weekend, and at first I thought he was defending the excessively loose monetary policy that led to the recent crisis.
Well, that didn't take long. It's only the first business day of the new year and big pharma's already gettin' down to business. Novartis is buying the rest of its Swiss neighbor Alcon for a cool $38.5 billion.
Usually I wouldn’t devote a blog to a biotech with a market value of approximately $86 million. But when your personal story goes Hollywood—as in mega-watt stars like Harrison Ford and Brendan Fraser playing the lead roles in the movie—then you get a blog.
Markets held gains on Tuesday after reports showed US home prices stabilized and consumer confidence improved. What should investors expect in the New Year and how should they be positioned? Tobias Levkovich, chief U.S. equity strategist at Citigroup, shared his strategies.
When I blogged last week about GlaxoSmithKline using the word “suck” in its new Nicorette ad campaign I thought it would be a one and done thing.
Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.
Futures mostly shrugged off news that weekly unemployment claims hit their lowest level in 15 months, but stocks were still poised for a gain in a holiday-shortened session Thursday.
Plus, get calls on the BlackBerry outage, pharma, dividends and more.
I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.
It's New Year's resolution time, so it's no surprise to see a sudden increase in commercials and ads for stop-smoking products. Pfizer's been heavily pushing its challenged Chantix and the other day I saw a commercial for GlaxoSmithKline's Nicorette that nearly made my jaw drop.
As senators made their way to Capitol Hill this weekend, a confluence of meteorological conditions conspired to dump nearly two feet of snow on Washington, DC. Unlike the decisions being made under the Capitol dome, we’ll soon dig ourselves out from the mountains of snow.
Australian vaccine maker CSL said on Monday its pandemic H1N1 swine flu vaccine delivered a strong immune response after just one dose in children as young as 6 months
This morning biopharma P & A reached critical mass. In a rare, holiday-week confluence, four major pharmaceutical companies announced partnership deals and one announced a nearly $2-billion acquisition. All of the partnerships are on drugs that are still in the testing stage. If they were to all come to fruition, which in the risky business of drug development is highly unlikely, the new partnerships could collectively be worth billions of dollars over time.
If you have had the misfortune to follow this debate as it grinds through the Senate, several thoughts come to mind.
There is nothing in this bill that changes our views at Soleil regarding the health care stocks we have been recommending.
We are almost halfway through the dollar rally, Robin Griffiths from Cazenove Capital said Monday. Griffiths sees stock markets "topping" in March next year.